<code id='08CDB94421'></code><style id='08CDB94421'></style>
    • <acronym id='08CDB94421'></acronym>
      <center id='08CDB94421'><center id='08CDB94421'><tfoot id='08CDB94421'></tfoot></center><abbr id='08CDB94421'><dir id='08CDB94421'><tfoot id='08CDB94421'></tfoot><noframes id='08CDB94421'>

    • <optgroup id='08CDB94421'><strike id='08CDB94421'><sup id='08CDB94421'></sup></strike><code id='08CDB94421'></code></optgroup>
        1. <b id='08CDB94421'><label id='08CDB94421'><select id='08CDB94421'><dt id='08CDB94421'><span id='08CDB94421'></span></dt></select></label></b><u id='08CDB94421'></u>
          <i id='08CDB94421'><strike id='08CDB94421'><tt id='08CDB94421'><pre id='08CDB94421'></pre></tt></strike></i>

          Home / explore / comprehensive

          comprehensive


          comprehensive

          author:explore    Page View:21795

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In